Showing results (2901-2910 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|December 1, 1988
Circadian rhythm and seasonal dependence in the toxicological response of mice to epirubicinM C Mormont, R von Roemeling, R B Sothern, et al.
Investigational New Drugs|December 1, 1988
Changes in drug sensitivity of a human astrocytoma clone previously treated with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea in vitroS C Barranco, C M Townsend, V K Jenkins, et al.
Investigational New Drugs|April 10, 2020
Structure-based design, synthesis, and evaluation of the biological activity of novel phosphoroorganic small molecule IAP antagonistsAgnieszka Łupicka-Słowik, Mateusz Psurski, Renata Grzywa, et al.
Investigational New Drugs|October 27, 2019
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinomaAnthony Wood, Saby George, Nabil Adra, et al.
Investigational New Drugs|October 23, 2019
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)Ruud van der Noll, Agnes Jager, Joo Ern Ang, et al.
Investigational New Drugs|August 5, 2021
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibitionJulian Taugner, Lukas Käsmann, Monika Karin, et al.
Investigational New Drugs|August 12, 2021
In vitro selection of DNA aptamers against human osteosarcomaKhaliunsarnai Tsogtbaatar, Diana A Sousa, Debora Ferreira, et al.
Investigational New Drugs|June 20, 2020
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumabMotohiro Tamiya, Kei Kunimasa, Kazumi Nishino, et al.
Investigational New Drugs|June 15, 2020
First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjectsMeng-Na Wang, Yun Kuang, Li-Ying Gong, et al.
Investigational New Drugs|November 6, 2004
Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98)Georg A Bjarnason, Danielle Charpentier, Ralph Wong, et al.
Pageof 372